医学
杜皮鲁玛
特应性皮炎
食品药品监督管理局
皮肤病科
全身疗法
疾病
重症监护医学
药品
药物治疗
生物制剂
内科学
药理学
癌症
乳腺癌
作者
Mary Kate Lockhart,Elaine C. Siegfried
标识
DOI:10.1016/j.det.2021.12.002
摘要
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in children. Standard-of-care treatment has been topical therapy. Oral corticosteroids are also commonly used to treat intermittent flares, despite guidelines that recommend against this practice. In 2017, the first targeted biologic agent indicated for moderate-severe AD in adults received US Food and Drug Administration approval. The success of this drug, dupilumab, filled a significant unmet medical need and inspired additional interest in new drug development. This article summarizes safe and effective use of systemic therapy for moderate-severe AD in pediatric patients, highlighting dupilumab and the most promising emerging treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI